As one of the fastest growing markets globally, China is a key market for companies competing in the Advanced Dressings Market. China is the second largest Advanced Dressings Market in the world and is projected to grow in the high single digits over the next five years according to SmartTRAK estimates. Not surprisingly, most of the global leaders in the Advanced Dressings Market have a presence in China, either via distributors or a direct sales force or through manufacturing sites, including Coloplast, WEGO, Mölnlycke and Smith+Nephew, among others.

To find out more about these companies and what’s new in the China Advanced Dressings Market, SmartTRAK highlights market updates covering the top news on new products, clinical studies, deals/financing, market trends, clinical/regulatory and company revenues. Following are some recent updates that were gathered and curated by our expert analysts and sent out to subscribers in SmartTRAK's Daily Updates. To discover how to learn more about the China Advanced Dressings Market, click here.

New Products:

• China NMPA Approvals in August
  

  In August 2022, NMPA approved 210 medical devices. Among them, 161 were domestic Class III devices, 25 imported Class III and 22 imported Class II devices. One NPWT kit from Nantong Changyu Medical Technology Co., Ltd. was the only wound care product.

• LUOFUCON Silicone Foam Border - Foryou Medical Devices Co.*

  ForYou Medical announced that they received a China NMPA approval for LUOFUCON Silicone Foam to be sold in China. Class III, National Machinery Note 20223140748. The dressing is manufactured by ForYou Medical, available in several anatomical shapes.

Dr. Kim outlines his extensive experience in adopting endoscopic spine surgery and reflects on barriers to widespread adoption, including the learning curve and reimbursement challenges

Endoscopic and arthroscopic technology has been around for a number of years, aiding surgeons’ visualization to treat patients in much less invasive ways than were previously possible. Prior to the introduction and adoption of these types of technology, surgeons were faced with invasive, more traumatic procedures and sometimes limitations on visualization based on anatomy. Less invasive approaches have allowed patients to benefit from less risk, shorter hospital stays and, in many cases, quicker healing.

Endoscopic approaches to spine surgery have been taking place for 10+ years, but the market hasn’t experienced transformative growth. All the patient benefits align with relative adoption trends, so why haven’t we seen endoscopic spine surgery grow at a similar rate? What does the future look like in this segment? SmartTRAKsat down with minimally invasive spine surgery pioneer Choll Kim, MD, PhD to explore his thoughts on focusing his minimally invasive surgical practice around specific offering of endoscopic spinal techniques, what the pros and cons have been within the adoption curve of the technology and where he thinks the market is headed.

SmartTRAK's spine experts will be roaming the floor at NASS 2022, bringing our subscribers real-time news direct from the show. We'll also be on the show floor at booth #2341, ready to answer your questions, share insights on the latest news and innovations in the Spine Market and discuss how SmartTRAK can help you Be the Expert in your market.  If you would like to book a meeting with us at NASS, please click here.

Continue reading to find out how to download a complete transcript of SmartTRAK's interview with Dr. Kim.

A market fraught with challenging hospital budgets, chip shortages and continued staffing issues results in apparent swings in robotic performance. On the other hand, enabling tech platforms companies continue to report positive momentum moving into H222.

The Q222 WW CAS Spine Market was down YoY according to SmartTRAK Financial Dashboard. Medtronic* (MDT) remained the market leader, followed by Globus* (GMED) and other enabling tech competitors including Stryker* (SYK) and Brainlab*. For detailed Q222 revenues and shares by company in the US, EU and ROW, see SmartTRAK CAS Spine Financial Dashboard*.

Among the many topics covered in detail in our comprehensive Q222 Computer Assisted Surgery Spine Market Recap* are:

• Complete Q222 CAS Spine Market Overview and Highlights
• SmartTRAK's Expert Analysis and Insights
• All Company News including Revenues, Data, Charts and Shares
• Variable Robotics Performance in a Difficult Climate

SmartTRAK highlights novel diagnostic devices for pressure ulcer (PU) prevention and interviews PU Sensor’s CEO Johannes Walfidsson at EPUAP 2022

According to SmartTRAK incidence and prevalence data*, there were over 10 million pressure ulcers in Europe in 2021, with four million being stage III to IV. This means that pressure ulcers account for around two-thirds of the total number of chronic wounds on the continent and almost half of the hard-to-heal wounds. Given these eye-opening statistics, it would be understandable to expect that the first European Pressure Ulcer Advisory Panel (EPUAP) Meeting in three years would indicate growing engagement in this area, both clinically and commercially. Unfortunately, on the evidence of the event in Prague, this wasn’t the case, with delegate numbers declining from previous years and a sparse exhibition hall missing many of the prominent wound care players. This begs the question; why isn’t there a greater focus on pressure ulcers and prevention? (Click to listen to SmartTRAK's interview with PU Sensor's CEO Johannes Walfidsson, "Advancing Risk Assessment for Pressure Ulcers." You can also download a complete transcript of the interview here)

SmartTRAK is pleased to announce that Joe Mish has been named new VP of Sales and will lead our commercial team. Before joining SmartTRAK two years ago, originally as Director of Sales, Joe had 10+ years experience in medical device sales, with a concentration on Joint Replacement and Spine & Robotic Technologies. Joe sold and implemented analytic software to manage value-based care and bundled payment, working with Stryker, LDR/ZimmerBiomet and Stryker Performance Solutions.

"I couldn't be more pleased to have a true professional with data analytics/IT/SaaS plus medical device background like Joe in this position. I think you will agree that he is the right person to bring SmartTRAK to the next level." - SmartTRAK CEO Sharon O'Reilly

Meet Joe Mish, SmartTRAK's new VP of Sales: 

What do you like about SmartTRAK? I truly love the value we bring to our customers. With the world being so volatile and medical device markets still being disrupted in so many ways, we offer clients a predictable way to stay ahead of their competition. This is extremely rare. There is no better feeling than standing behind a company and product that you really believe in…we are focused and committed to building long term relationships and strategic partnerships with our customers, and it shows.

WW Advanced Wound Care continues to grow in the mid-single-digits as company revenues reflect normalcy in wound care with a likely increase in wound severity.

For Q222, SmartTRAK Financial Dashboard reports the WW Advanced Wound Care (AWC) market grew +6.4%. WW Advanced Dressings and WW Wound Biologics were also up, while NPWT-heavy External Devices revenue increased marginally.

Among the many topics covered in detail in our comprehensive Q222 Advanced Wound Care Market Recap* are:

• Complete Q222 AWC Overview and Highlights
• SmartTRAK's Expert Analysis and Insights
• All Company News including Revenues, Data, Charts and Shares
• Growth Analysis – Currency Having a Significant Impact in Q2

SmartTRAK highlights key movements in the quickly changing landscape of interventional pain management and identifies practice trends surrounding SCS, PNS, minimally invasive spine and SI Joint Fusion from the recent ASPN and INS meetings.

Strong demand for alternatives to narcotic pain management combined with an aging population and growing incidence of chronic pain continue to drive demand for interventional pain techniques. The approach to the treatment of chronic intractable pain is evolving, with a shift toward data-focused treatment optimization, growing use of digital monitoring and holistic evaluation of patient outcomes. Furthermore, increasing overlap among various devices and therapies as well as unclear boundaries between interventional pain, orthopedic and spine practices is spurring physicians to adopt collaborative approaches to patient care.

Among the many timely topics covered in this comprehensive Market Outlook article "Pain Intervention: A Market of Moving Targets", which can be downloaded in its entirety here, are:

Among the many topics covered in detail in our comprehensive Q222 Extremities Market Recap* are: